Harnessing epitope reciprocity and multimeric epitope density for a novel multiepitope vaccine design against Acinetobacter baumannii.

Acinetobacter baumannii, a notorious nosocomial pathogen, presents a global health challenge due to its high antibiotic resistance and ability to cause various infections. Vaccine development against this pathogen is a pressing need, yet traditional methods have encountered limitations due to the immunogenic complexity and potential autoimmune risks associated with key antigenic components. In this study, we leveraged the reverse vaccinology approach, integrating epitope mapping, immunoinformatics, and structural modeling to design a novel multiepitope vaccine. Our methodology emphasizes the concept of epitope reciprocity, wherein B-cell and T-cell epitopes are co-localized to promote cross-epitope interactions, enhancing immunogenicity and immune response synergy. Additionally, utilizing a trimeric construct, we achieved a threefold increase in epitope density, further amplifying the immune activation potential. Key antigenic proteins implicated in the pathogenicity of A. baumannii were screened, excluding components like OmpA, which is known to induce autoimmune responses. After rigorous silico analyses, including structural validation and molecular docking, the final construct demonstrated promising interaction with Toll-like receptor 1 (TLR-1), suggesting efficient immune recognition. This multiepitope design, grounded in the principles of epitope reciprocity and enhanced by multimeric epitope density, offers a promising platform for developing a safe and effective vaccine against A. baumannii. Further experimental validation is warranted to assess its in vivo efficacy and safety.